BMO Capital Upgrades Nektar Therapeutics (NKTR) to Outperform

September 22, 2009 9:26 AM EDT Send to a Friend
Get Alerts NKTR Hot Sheet
Price: $10.87 +0.37%

Rating Summary:
    7 Buy, 1 Hold, 2 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 27 | Down: 8 | New: 16
Trade NKTR Now!
Join SI Premium – FREE
BMO Capital upgrades Nektar Therapeutics (Nasdaq: NKTR) from Market Perform to Outperform. Price target $12.

To see more analyst ratings on NKTR Click Here.

Nektar Therapeutics, a biopharmaceutical company, develops various drug products and product candidates using its proprietary drug delivery technologies.

You May Also Be Interested In

Related Categories


Related Entities

BMO Capital

Add Your Comment